Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
norelgestromin+ ethinyl estradiol; mercilon · 3 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| norelgestromin + ethinyl estradiol | DRUG | - |
| norelgestromin + ethinyl estradiol; mercilon | DRUG | - |
| norelgestromin + ethinyl estradiol; triphasil. | DRUG | - |
Inclusion Criteria: * Healthy women with regular menstrual cycles * sexually active and at risk of pregnancy * nonpregnant * acceptable body mass index (BMI) * last term pregnancy at least 42 days prior, nonlactating, with 1 normal menstrual cycle since * sitting BP\<140mmHg/\<90mmHg * 1 normal men...
Norelgestromin + ethinyl estradiol, also known as Mercilon, is a combination contraceptive used for the prevention of pregnancy. It is being developed by Johnson & Johnson (JNJ) and is currently in Phase 3 clinical development for contraception, within the therapeutic area of endocrine disorders.
Norelgestromin + ethinyl estradiol is a combination of two hormones: norelgestromin, a progestin, and ethinyl estradiol, an estrogen. These hormones work together to prevent ovulation and thicken cervical mucus, making it harder for sperm to reach the uterus. This combined mechanism provides effective contraception.
Norelgestromin + ethinyl estradiol, also known as Mercilon, is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the NYSE under the ticker JNJ. The drug is currently in Phase 3 clinical trials for contraception.
Norelgestromin + ethinyl estradiol (Mercilon) is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. Three Phase 3 trials have been completed, with a total enrollment of 4,762 participants, all focused on contraception.
Norelgestromin + ethinyl estradiol (Mercilon) has completed three Phase 3 clinical trials: NCT00236769, NCT00236782, and NCT00236795. These studies evaluated the efficacy and safety of the transdermal contraceptive system, with two trials comparing it against Mercilon and Triphasil, respectively. All trials enrolled healthy female participants aged 18 years and older.
Yes, norelgestromin + ethinyl estradiol is also known as Mercilon. The drug is a combination contraceptive being developed by Johnson & Johnson (JNJ) for the prevention of pregnancy. It is currently in Phase 3 clinical development, with three completed trials evaluating its efficacy and safety.